The Genivent team has been investing in alternatives for decades and is opportunistically targeting accretive secondary transactions and GP equity positions. Genivent has an unconstrained mandate and acts as a dedicated liquidity sleeve for Omnigence Partner funds.
The team has been investing in farmland since 2007 and lower market private equity since 2013. We know the assets, values, operations and prospects of the Omnigence partner funds intimately, reducing information asymmetry risk that is common in secondary markets.
Genivent is typically able to transact secondaries at material discounts to par/NAV and has dedicated access to a large, ongoing pool of LP investors in the partner funds.
Unique uncorrelated return profiles via GP stakes, gross up from underlying return profiles, higher underlying asset liquidity, shorter portfolio to duration than primary investment.
We access the real-time reporting and monitoring systems of the underlying funds to rapidly and accurately monitor and deliver the information about Genivent’s holdings.
Secondary discounts, embedded gain in GP stake value, short implied portfolio duration, high run rate distributions combine to mitigate risk.